France curbs drug costs by tightening reimbursement rules
France is managing rising healthcare costs by restricting state reimbursement to drugs that prove clear clinical superiority, a policy that directly shapes pharmaceutical market access.
The French state healthcare system is strictly controlling pharmaceutical spending by refusing to reimburse medicines that fail to demonstrate sufficient clinical benefit over existing treatments. The policy, enforced by the health ministry based on evaluations from the Haute Autorité de Santé (HAS), separates a drug's authorisation to sell from its eligibility for public funding.
For pharmaceutical companies operating in Europe's second-largest market, this creates a high hurdle for market access. To secure reimbursement, a drug must appear on the official state list, be prescribed by an authorised professional, and be used strictly within its approved therapeutic indications. The HAS evaluates a drug's Service Médical Rendu—its actual medical benefit—and its improvement over existing therapies before advising the ministry.
The economic rationale is driven by the influx of expensive new therapies, which forces public health authorities to prioritise resources. A prominent example is Ozempic, which the Assurance Maladie refuses to reimburse when prescribed solely for obesity. Coverage is restricted to certain patients with type 2 diabetes under strict conditions.
France is not closing the door on obesity treatments entirely, but is selectively choosing which therapies to fund. The state will begin reimbursing the obesity medicines Wegovy and Mounjaro from June 2026, signalling a calculated shift toward newer, specifically targeted drugs as older ones are restricted.
The system also actively removes older medicines from the reimbursement list when budgets need reallocating. Homeopathy was entirely delisted in 2021 after authorities determined the funding would be better spent elsewhere. Medicines are routinely downgraded when newer, more effective alternatives enter the market.
Even when a drug makes the list, the state caps its financial exposure through a tiered reimbursement system. Rates are set at 15 percent for drugs offering low medical benefit, 30 percent for moderate benefit, and 65 percent for significant benefit. A 100 percent rate is reserved for treatments deemed irreplaceable and expensive, or for patients with serious chronic illnesses enrolled in the long-term illness program. The remaining costs are typically shifted to private complementary health insurance.
To further drive down costs, France is expanding its substitution rules. Starting September 1, 2026, pharmacists will be able to substitute brand-name drugs with hybrid or biosimilar medicines. Patients who refuse these cheaper alternatives without a medical exemption will only be reimbursed at the lower substitute rate, forcing them to absorb the price difference.
